ArticleChest2026
Impact of Positive Airway Pressure Therapy on Health Care Resource Use in Patients With OSA and Coronary Artery Disease.
Article in Chest, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The Global Initiative for Obstructive Sleep Apnea (GIFOSA): Rationale, Strategic Framework, and Call to Action.Pulmonary therapy · 2026Review
- Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundOSA is associated with coronary artery disease (CAD) risk. This study examined the impact of positive airway pressure (PAP) therapy adherence on health care resource use (HCRU) in patients with CAD and newly diagnosed OSA. RESEARCH QUESTION: Is adherence to PAP therapy associated with reduced HCRU in patients with CAD and OSA? STUDY DESIGN AND
methodsThis retrospective analysis linked administrative claims to objective PAP use data (ResMed AirView) for adults (≥ 18 years of age) with CAD who received a new diagnosis of OSA. Two-year adherence was defined by the number of 90-day time frames in which adherence criteria were met. Inverse probability of treatment weighting was applied to assess primary outcomes of emergency room (ER) visits and hospitalizations 1 and 2 years after the index date.
resultsThirty-two thousand nine hundred eleven patients were included (34.9% female; mean age, 60.9 years). Compared with adherent patients, nonadherent patients were slightly younger, more commonly female, and had higher prevalence of severe obesity and comorbidities. Compared with nonadherent patients, adherent patients made significantly fewer ER visits (-26% and -24%; P < .001) and all-cause hospitalizations (-35% and -39%; P < .001) in years 1 and 2, respectively. HCRU for intermediately adherent patients fell between that of adherent and nonadherent patients. After risk adjustment, the threshold for minimum nightly PAP use to derive a significant HCRU benefit was < 3 h/night for all outcomes and periods. A 4.7% to 5.9% reduction in HCRU rates with each additional hour per night of PAP use was noted.
interpretationIn real-world patients with CAD and newly diagnosed OSA, PAP therapy adherence was associated with lower HCRU. These findings strongly support the importance of diagnosing and treating OSA in these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.